These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37718575)

  • 1. Treatment-related outcome from patient report outcome (PRO) of children with severe and moderate hemophilia A in China: An analysis report of registration data from patient organization "hemophilia home care center".
    Guan T; Ai D; Zhao N; Liu G; Yao W; Chen Z; Li Z; Zhou Y; Wu R
    Haemophilia; 2023 Nov; 29(6):1467-1474. PubMed ID: 37718575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
    Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.
    Elalfy M; Elghamry I; Hassab H; Elalfy O; Andrawes N; El-Ekiaby M
    Haemophilia; 2022 Jan; 28(1):65-72. PubMed ID: 34797008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.
    Fischer K; Kenet G; Kurnik K; Carcao M; Oldenburg J; Stamm-Mikkelsen T; Cid Haro AR; Koskenvuo M; Blatny J; Königs C
    Blood Adv; 2024 Jan; 8(2):369-377. PubMed ID: 38214949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
    Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
    Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.
    Unuvar A; Warrier I; Lusher JM
    Haemophilia; 2000 May; 6(3):150-7. PubMed ID: 10792472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study.
    Scott MJ; Xiang H; Hart DP; Palmer B; Collins PW; Stephensen D; Sima CS; Hay CRM
    Haemophilia; 2019 Mar; 25(2):205-212. PubMed ID: 30408835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC; Liao YM; Tsai SP; Chang TT
    Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
    Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
    Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
    Kenet G; Oladapo A; Epstein JD; Thompson C; Novack A; Nugent DJ
    Haemophilia; 2017 Sep; 23(5):e394-e402. PubMed ID: 28641362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with rituximab-based immunosuppressive agent(s) in China.
    Li Z; Liu G; Yao W; Chen Z; Li G; Cheng X; Zhen Y; Ai D; Huang K; Sun J; Poon MC; Wu R
    Haemophilia; 2022 Jul; 28(4):625-632. PubMed ID: 35503087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical and economic outcomes in previously untreated paediatric patients with severe haemophilia A: A nationwide real-world study with 700 person-years.
    Vepsäläinen K; Riikonen P; Lassila R; Arola M; Huttunen P; Lähteenmäki P; Möttönen M; Selander T; Martikainen J
    Haemophilia; 2018 May; 24(3):436-444. PubMed ID: 29493848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].
    Zhuang JM; Sun XY; Zhou X; Liu ZQ; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Apr; 38(4):496-501. PubMed ID: 29735454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre real-world data study to assess the bleeding rate and management of patients with haemophilia A and factor VIII inhibitors in Argentina.
    Neme D; Ramos Mejía I; Elelhou L; Do Nascimento P; Arrieta ME; Cocca A; Saenz V; Davoli M
    Blood Coagul Fibrinolysis; 2021 Dec; 32(8):564-571. PubMed ID: 34776503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children.
    Chozie NA; Primacakti F; Gatot D; Setiabudhy RD; Tulaar ABM; Prasetyo M
    Haemophilia; 2019 Jul; 25(4):633-639. PubMed ID: 31044491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.